510(k) clearance for Boston Biomedica:
This article was originally published in Clinica
The FDA has given 510(k) approval to another four of Boston Biomedica's Accurun quality control products. Two of the devices are multi-analyte controls for blood bank viral marker screening and the others are single analyte controls for ToRCH (Toxoplasmosis, Rubella, Cytomegalovirus, and Herpes) - the group of infections which are especially harmful when contracted during pregnancy. The US company's range of Accurun products is used by blood banks, IVD manufacturers and clinical and research laboratories to ensure the accuracy of results of infectious disease tests by monitoring test performance.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.